NGF and VEGF effects on retinal ganglion cell fate: New evidence from an animal model of diabetes

European Journal of Ophthalmology

Volumn 24, Issue 2, 2013, Pages 247-253

  Mantelli, Flavio ^a   Lambiase, Alessandro ^b   Colafrancesco, Valeria ^c   Rocco, Maria Luisa ^c   Macchi, Ilaria ^b   Aloe, Luigi ^c  

^a IRCCS FONDAZIONE BIETTI   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c CNR   (Italy)

Author keywords

Diabetic retinopathy; Nerve growth factor; Retinal ganglion cells; TrkA; Vascular endothelial growth factor

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR ANTIBODY; PROTEIN TYROSINE KINASE A; STREPTOZOCIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FATE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; GLYCEMIC INDEX; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA DEGENERATION; RETINA GANGLION CELL;

ANIMALS; ANTIBODIES, BLOCKING; BLOOD GLUCOSE; CELL SURVIVAL; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; MALE; NERVE GROWTH FACTOR; OPHTHALMIC SOLUTIONS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, TRKA; RETINA; RETINAL DEGENERATION; RETINAL GANGLION CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84892729871     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000359     Document Type: Article

References (30)

1. Lorenzi M, Gerhardinger C. Early cellular and molecular changes induced by diabetes in the retina. Diabetologia 2001;44:791-804.
2. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med 2012;366:1227-1239.
3. Whitmire W, Al-Gayyar MM, Abdelsaid M, Yousufzai BK, El-Remessy AB. Alteration of growth factors and neuronal death in diabetic retinopathy: what we have learned so far. Mol Vis 2011;17:300-308.
4. Hammes HP, Federoff HJ, Brownlee M. Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol Med 1995;1:527-534.
5. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987;237:1154-1162.
6. Lambiase A, Mantelli F, Bonini S. Nerve growth factor eye drops to treat glaucoma. Drug News Perspect 2010;23:361-367.
7. Lambiase A, Aloe L, Centofanti M, et al. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: implications for glaucoma. Proc Natl Acad Sci USA 2009;106:13469-13474.
8. Lambiase A, Mantelli F, Sacchetti M, Rossi S, Aloe L, Bonini S. Clinical application of NGF in ocular diseases. Arch Ital Biol 2011;149:283-292.
9. Lambiase A, Tirassa P, Micera A, Aloe L, Bonini S. Pharmacokinetics of conjunctivally applied nerve growth factor in the retina and optic nerve of adult rats. Invest Ophthalmol Vis Sci 2005;46:3800-3806.
10. Lambiase A, Aloe L. Nerve growth factor delays retinal degeneration in C3H mice. Graefes Arch Clin Exp Ophthalmol 1996;234(Suppl 1):S96-S100.
11. Chiaretti A, Falsini B, Servidei S, Marangoni D, Pierri F, Riccardi R. Nerve growth factor eye drop administration improves visual function in a patient with optic glioma. Neurorehabil Neural Repair 2011;25:386-390.
12. Nakamura K, Tan F, Li Z, Thiele CJ. NGF activation of TrkA induces vascular endothelial growth factor expression via induction of hypoxia-inducible factor-1α. Mol Cell Neurosci 2011;46:498-506.
13. Colafrancesco V, Cirulli F, Rossi S, Berry A, Aloe L. Anti-NGFantibody administration as collyrium reduces the presence of NGF and enhances the expression of VEGF in the retina, lacrimal gland and hippocampus. Neurosci Lett 2009;463:203-206.
14. Jee D, Lee WK. Inhibitory effect of intravitreal injection of bevacizumab on nerve growth factor. Curr Eye Res 2012;37:408-415.
15. Colafrancesco V, Coassin M, Rossi S, Aloe L. Effect of eye NGF administration on two animal models of retinal ganglion cells degeneration. Ann 1st Super Sanita 2011;47:284-289.
16. Hammes HP, Federoff HJ, Brownlee M. Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol Med 1995;1:527-534.
17. Bocchini V, Angeletti PU. The nerve growth factor: purification as a 30,000-molecular-weight protein. Proc Natl Acad Sci USA 1969;64:787-794.
18. Stoeckel K, Gagnon C, Guroff G, Thoenen H. Purification of nerve growth factor antibodies by affinity chromatography. J Neurochem 1976;26:1207-1211.
19. Lambiase A, Centofanti M, Micera A, et al. Nerve growth factor (NGF) reduces and NGF antibody exacerbates retinal damage induced in rabbit by experimental ocular hypertension. Graefes Arch Clin Exp Ophthalmol1997;235:780-785.
20. Siliprandi R, Canella R, Carmignoto G. Nerve growth factor promotes functional recovery of retinal ganglion cells after ischemia. Invest Ophthalmol Vis Sci 1993;34:3232-3245.
21. Carmignoto G, Maffei L, Candeo P, Canella R, Comelli C. Effect of NGF on the survival of rat retinal ganglion cells following optic nerve section. J Neurosci 1989;9:1263-1272.
22. Coassin M, Lambiase A, Sposato V, Micera A, Bonini S, Aloe L. Retinal p75 and bax overexpression is associated with retinal ganglion cells apoptosis in a rat model of glaucoma. Graefes Arch Clin Exp Ophthalmol 2008;246:1743-1749.
23. Barker PA. p75NTR is positively promiscuous: novel partners and new insights. Neuron 2004;42:529-533.
24. Bronfman FC, Fainzilber M. Multi-tasking by the p75 neurotrophin receptor: sortilin things out? EMBO Rep 2004; 5:867-871.
25. Tirassa P, Maccarone M, Florenzano F, Cartolano S, De Nicolò S. Vascular and neuronal protection induced by the ocular administration of nerve growth factor in diabeticinduced rat encephalopathy. CNS Neurosci Ther 2013;19: 307-318.
26. Al-Gayyar MM, Matragoon S, Pillai BA, Ali TK, Abdelsaid MA, El-Remessy AB. Epicatechin blocks pro-nerve growth factor (proNGF)-mediated retinal neurodegeneration via inhibition of p75 neurotrophin receptor expression in a rat model of diabetes [corrected]. Diabetologia 2011; 54:669-680.
27. Ali TK, Al-Gayyar MM, Matragoon S, et al. Diabetes-induced peroxynitrite impairs the balance of pro-nerve growth factor and nerve growth factor, and causes neurovascular injury. Diabetologia 2011;54:657-668.
28. Faradji V, Sotelo J. Low serum levels of nerve growth factor in diabetic neuropathy. Acta Neurol Scand 1990;81: 402-406.
29. Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA; NGF Study Group. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. Neurology 1998;51:695-702.
30. Park HJ, Kim MN, Kim JG, et al. Up-regulation of VEGF expression by NGF that enhances reparative angiogenesis during thymic regeneration in adult rat. Biochim Biophys Acta 2007;1773:1462-1472.